Digestive Care's PEP gets FDA complete response
This article was originally published in Scrip
Executive Summary
Digestive Care's pancreatic enzyme product (PEP) Pancrecarb (pancrelipase delayed release) has met with a complete response letter from the US FDA for the treatment of exocrine pancreatic insufficiency, but the company says it is not required to conduct additional trials before NDA approval.